Improving the effectiveness of COVID-19 vaccines with new adjuvant strategies
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy
This study is working on making COVID-19 vaccines even better by using special ingredients that help boost your immune system, especially for older adults, so they can have stronger and longer-lasting protection against the virus and its new variants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11109391 on NIH RePORTER |
What this research studies
This research focuses on enhancing the efficacy of SARS-CoV-2 vaccines by developing a combination of adjuvants that stimulate the immune system more effectively. The approach aims to create a vaccine that not only provides long-lasting protection but also adapts to emerging variants of the virus. By targeting key pathways in the immune response, the study seeks to ensure that the vaccine is particularly effective for vulnerable populations, such as the elderly. Patients may benefit from a more robust and durable immune response against COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at higher risk for severe COVID-19 outcomes, including the elderly and those with compromised immune systems.
Not a fit: Patients who have already received a COVID-19 vaccine that provides adequate protection may not see additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to vaccines that offer stronger and longer-lasting protection against COVID-19, especially for high-risk groups.
How similar studies have performed: Previous research has shown that innovative adjuvant strategies can significantly enhance vaccine responses, suggesting a promising avenue for improving COVID-19 vaccine efficacy.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wong, Pamela Tinmoi — University of Michigan at Ann Arbor
- Study coordinator: Wong, Pamela Tinmoi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.